Reply to Pollock, Donta, Wilson, and Arnež [5]

Clinical Infectious Diseases

Volumn 44, Issue 8, 2007, Pages 1137-1139

  Wormser, Gary P ^a   Dattwyler, Raymond J ^a   Shapiro, Eugene D ^d   Halperin, John J ^b,c   Steere, Allen C ^f   Klempner, Mark S ^g   Krause, Peter J ^e   Bakken, Johan S ^h   Strle, Franc ^j   Stanek, Gerold ^k   Bockenstedt, Linda K ^d   Fish, Durland ^d   Dumler, J Stephen ⁱ   Nadelman, Robert B ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Atlantic Neuroscience Institute   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h St Luke's Hospital   (United States)

ⁱ DEPARTMENT OF PATHOLOGY   (United States)

^j UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENZATHINE PENICILLIN;

ANTIBIOTIC THERAPY; BORRELIA BURGDORFERI; CULTURE MEDIUM; ERYTHEMA CHRONICUM MIGRANS; HUMAN; IMMUNE RESPONSE; LETTER; LYME DISEASE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SERODIAGNOSIS; SYMPTOMATOLOGY;

EID: 34147206479     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513029     Document Type: Letter

References (37)

1. Pollock AA. Accuracy of recommendations in the Infectious Diseases Society of America clinical practice guidelines for Lyme disease [letter]. Clin Infect Dis 2007; 44:1135 (in this issue).
2. Phillips SE, Mattman LH, Hulinska D, Moayad H. A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated. Infection 1998; 26:364-7.
3. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345:85-92.
4. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and pre-vention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089-134.
5. Marques AR, Stock F, Gill V. Evaluation of a new culture medium for Borrelia burgdorferi J Clin Microbiol 2000; 38:4239-41.
6. Tilton RC, Barden D, Sand M. Culture of Borrelia burgdorferi. J Clin Microbiol 2001; 39:2747.
7. Nadelman RB, Nowakowski J, Forseter G, et al. Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. Am J Med 1993; 94:583-8.
8. Berger BW, Johnson RC, Kodner C, Coleman L. Failure of Borrelia burgdorferi to survive in the skin of patients with antibiotic-treated Lyme disease. J Am Acad Dermatol 1992; 27:34-7.
9. Hunfeld KP, Ruzic-Sabljic E, Norris DE, Kraiczy P, Strle F. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother 2005; 49:1294-301.
10. Steere AC, Green J, Schoen RT, et al. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med 1985; 312:869-74.
11. Donta ST. Lyme disease guidelines: it's time to move forward [letter]. Clin Infect Dis 2007; 44:1134-5 (in this issue).
12. Shapiro ED, Dattwyler R, Nadelman RB, Wormser GP. Response to meta-analysis. Int J Epidemiol 2005; 34:1437-9.
13. Cairns V, Godwin J. Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 2005; 34:1340-5.
14. Buchwald D, Umali P, Umali J, Kith P, Pearlman T, Komaroff AL. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. Ann Intern Med 1995; 123:81-8.
15. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (stop-LD): a randomized double-masked clinical trial. Neurology 2003; 60:1923-30.
16. Donta ST. Macrolide therapy of chronic Lyme disease. Med Sci Monit 2003; 9:PI136-42.
17. Donta ST. Tetracycline therapy of chronic Lyme disease. Clin Infect Dis 1997; 25:S52-6.
18. Lightfoot RW, Luft BJ, Rahn DW, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic test for Lyme disease: a cost-effectiveness analysis. Ann Intern Med 1993; 119:503-9.
19. Akin E, McHugh GL, Flavell RA, Fikrig E, Steere AC. The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged arthritis and the IgG response to P35 correlates with mild and brief arthritis. Infect Immun 1999; 67:173-81.
20. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993; 167:392-400.
21. Pachner AR. The rhesus model of Lyme neuroborreliosis. Immunol Rev 2001; 183:186-204.
22. Wilson JM. Concerns regarding the Infectious Diseases Society of America Lyme disease clinical practice guidelines [letter]. Clin Infect Dis 2007; 44:1135-7 (in this issue).
23. Wessely S. Chronic fatigue: symptoms and syndrome. Ann Intern Med 2001; 134:838-43.
24. Croft P, Rigby AS, Boswell R, Schollum J, Silman A. The prevalence of chronic widespread pain in the general population. J Rheumatol 1993; 20:710-3.
25. Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005; 43:1078-86.
26. Zahran HS, Kobau R, Moriarty DG, et al. Health-related quality of life surveillance - United States, 1993-2002. MMWR Surveill Summ 2005; 54:1-35.
27. Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med 2003; 348:2472-4.
28. Halperin JJ, Golightly M. Lyme borreliosis in Bell's palsy. Long Island Neuroborreliosis Collaborative Study Group. Neurology 1992; 42:1268-70.
29. Bacon RM, Biggerstaff BJ, Schriefer ME, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003; 187:1187-99.
30. Steere AC, Taylor E, McHugh GL, Logigian EL. The over diagnosis of Lyme disease. JAMA 1993; 269:1812-26.
31. Rose CD, Fawcett PT, Gibney KM, Doughty RA. The overdiagnosis of Lyme disease in children residing in an endemic area. Clin Pediatr 1994; 33:663-8.
32. Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998; 128:354-62.
33. Burdge DR, O'Hanlon DP. Experience of a referral center for patients with suspected Lyme disease in an area of non-endemicity; first 65 patients. Clin Infect Dis 1993; 16:558-60.
34. Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995; 171:356-61.
35. Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM. Death from inappropriate therapy for Lyme disease. Clin Infect Dis 2000; 31:1107-9.
36. Arnež M. Antibiotic treatment of children with erythema migrans [letter]. Clin Infect Dis 2007; 44:1133-4 (in this issue).
37. Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 2002; 109:1173-7.